GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6475 MPPGSummary: mGlu receptor antagonist -
B6479 MDL 11,939Summary: 5-HT2A receptor antagonist -
B6483 LuzindoleSummary: Melatonin antagonist -
B6484 OleamideSummary: CB1 cannabinoid receptor agonist -
B6485 PalmitoylethanolamideSummary: GPR55 agonist -
B6489 BD 1063 dihydrochloride1 CitationSummary: σ1 receptor antagonist,potent and selective -
B6493 GR 135531Summary: MT3 receptor agonist -
B6508 ARC 239 dihydrochlorideSummary: α2B adrenoceptor antagonist -
B6509 ZD 7114 hydrochlorideSummary: β3-adrenoceptor agonist -
B6513 MK 212 hydrochlorideSummary: 5-HT2C receptor agonist

